Inactivation of human immunodeficiency virus type 1 by porphyrins

被引:91
|
作者
Vzorov, AN
Dixon, DW
Trommel, JS
Marzilli, LG
Compans, RW [1 ]
机构
[1] Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Chem, Atlanta, GA 30322 USA
[3] Georgia State Univ, Dept Chem, Atlanta, GA 30333 USA
关键词
D O I
10.1128/AAC.46.12.3917-3925.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have evaluated the anti-human immunodeficiency virus (HIV) activity of a series of natural and synthetic porphyrins to identify compounds that could potentially be used as microbicides to provide a defense against infection by sexually transmitted virus. For assays we used an epithelial HeLa-CD4 cell line with an integrated long terminal repeat-p-galactosidase gene. For structure-activity analysis, we divided the porphyrins tested into three classes: (i) natural porphyrins, (ii) metallo-tetraphenylporphyrin tetrasulfonate (metallo-TPPS4) derivatives, and (iii) sulfonated tetra-arylporphyrin derivatives. None of the natural porphyrins studied reduced infection by more than 80% at a concentration of 5 mug/ml in these assays. Some metal chelates of TPPS4 were more active, and a number of sulfonated tetra-aryl derivatives showed significantly higher activity. Some of the most active compounds were the sulfonated tetranaphthyl porphyrin (TNapPS), sulfonated tetra-anthracenyl porphyrin (TAnthPS), and sulfonated 2,6-difluoro-meso-tetraphenylporphine [TPP(2,6-F2)S] and its copper chelate [TPP(2,6-F2)S,Cu], which reduced infection by 99, 96, 94, and 96%, respectively. Our observations indicate that at least some of these compounds are virucidal, i.e., that they render the virus noninfectious. The active compounds were found to inhibit binding of the HIV type 1 gp120 to CD4 and also to completely inhibit the ability of Env proteins expressed from recombinant vectors to induce cell fusion with receptor-bearing target cells. These results support the conclusion that modified porphyrins exhibit substantial activity against HIV and that their target is the HIV Env protein.
引用
收藏
页码:3917 / 3925
页数:9
相关论文
共 50 条
  • [1] INACTIVATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BY ALCOHOLS
    VANBUEREN, J
    LARKIN, DP
    SIMPSON, RA
    JOURNAL OF HOSPITAL INFECTION, 1994, 28 (02) : 137 - 148
  • [2] INACTIVATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BY OZONE INVITRO
    WELLS, KH
    LATINO, J
    GAVALCHIN, J
    POIESZ, BJ
    BLOOD, 1991, 78 (07) : 1882 - 1890
  • [3] INACTIVATION OF HUMAN-IMMUNODEFICIENCY-VIRUS
    KONDRATEV, KJ
    NOSIK, DN
    TELEGINA, TA
    KORNEEVA, MN
    KUZNETSOVA, NV
    FEDCHENKO, PP
    DOKLADY AKADEMII NAUK SSSR, 1990, 314 (03): : 739 - 741
  • [4] Identification of a Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Variant Resistant to Cold Inactivation
    Kassa, Aemro
    Finzi, Andres
    Pancera, Marie
    Courter, Joel R.
    Smith, Amos B., III
    Sodroski, Joseph
    JOURNAL OF VIROLOGY, 2009, 83 (09) : 4476 - 4488
  • [5] Novel method of inactivation of human immunodeficiency virus type 1 by the freeze pressure generation method
    Otake, T
    Kawahata, T
    Mori, H
    Kojima, Y
    Hayakawa, K
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2005, 67 (06) : 746 - 751
  • [6] CD4-IgG binding threshold for inactivation of human immunodeficiency virus type 1
    Berkower, I
    Mostowski, H
    Bull, TE
    Murphy, D
    JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (04): : 863 - 869
  • [7] Novel method of inactivation of human immunodeficiency virus type 1 by the freeze pressure generation method
    T. Otake
    T. Kawahata
    H. Mori
    Y. Kojima
    K. Hayakawa
    Applied Microbiology and Biotechnology, 2005, 67 : 746 - 751
  • [8] Intrabodies to human immunodeficiency virus type 1
    Paillard, F
    HUMAN GENE THERAPY, 1999, 10 (09) : 1425 - 1427
  • [9] Assembling the human immunodeficiency virus type 1
    Cimarelli, A
    Darlix, JL
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2002, 59 (07) : 1166 - 1184
  • [10] Rapid sequon evolution in human immunodeficiency virus type 1 relative to human immunodeficiency virus type 2
    Wills, C
    Farmer, A
    Myers, G
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (14) : 1383 - 1384